Ashwagandha and Your Heart: What the Research Says

Cardiovascular research on ashwagandha (Withania somnifera) sits at a curious junction: many of the documented effects of this adaptogen — cortisol reduction, cholesterol improvement, blood pressure modulation, enhanced aerobic capacity — are directly relevant to heart health. Yet there is no dedicated large-scale clinical trial studying ashwagandha for cardiovascular disease outcomes specifically.

What exists is a constellation of mechanistic and biomarker data. Understanding what that constellation means — and what it does not — requires a concept we call the stress-cardiovascular relay: the chain by which chronic psychological stress activates the HPA axis, elevates cortisol and inflammatory markers, and progressively damages the cardiovascular system through multiple simultaneous pathways.

Ashwagandha does not directly "protect" the heart in the way a cardiologist would define that. What it may do is interrupt the stress-driven relay at several points simultaneously.

The Pathways: How Ashwagandha May Support Cardiovascular Health

1. Cortisol and Cardiovascular Risk

Chronic cortisol elevation is independently associated with increased cardiovascular disease risk. The mechanisms include: elevated blood pressure (cortisol sensitises blood vessels to vasoconstrictors), increased visceral adiposity (a major cardiovascular risk factor), impaired vascular endothelial function, and promotion of atherogenic lipid profiles.

Ashwagandha's documented cortisol-reducing effects (meta-analysis: PMID: 39348746, 40746175) therefore have indirect cardiovascular relevance. This is not a direct cardioprotective effect — it is upstream stress pathway modulation.

2. Lipid Profile Improvements

The 2020 metabolic meta-analysis (PMID: 31975514) found significant reductions in total cholesterol, LDL cholesterol, and triglycerides in human ashwagandha studies. These are established cardiovascular risk markers.

The mechanisms proposed include: reduced cortisol-driven hepatic cholesterol synthesis, withanolide effects on lipid metabolism (prepreliminary research), and anti-inflammatory effects reducing oxidative modification of LDL particles.

A 2025 RCT (PMID: 41635453) examining ashwagandha for stress and weight management reported cardiovascular markers as secondary outcomes, with improvements consistent with the earlier meta-analysis data.

3. VO2max and Aerobic Capacity

This is perhaps the most underappreciated cardiovascular-relevant finding in the ashwagandha literature. A 2020 meta-analysis (PMID: 32316411) found significant improvements in VO2max — the gold-standard measure of cardiovascular fitness — in both healthy adults and athletes taking ashwagandha.

VO2max is one of the strongest independent predictors of cardiovascular disease mortality. Low VO2max is a more powerful predictor of early death than traditional risk factors like smoking and hypertension in some analyses. Improving VO2max through ashwagandha — even modestly — has potential long-term cardiovascular significance.

The proposed mechanism: ashwagandha reduces exercise-induced cortisol (the catabolic stress response to training), allowing faster recovery and progressive aerobic adaptation. It does not directly increase cardiac output; it appears to improve the recovery environment that allows training adaptations to accumulate.

4. Anti-inflammatory Effects

Chronic low-grade inflammation is central to atherosclerosis progression. Withanolides, the primary bioactive compounds in ashwagandha root, have demonstrated anti-inflammatory effects in multiple studies — including reductions in high-sensitivity CRP (hs-CRP) and other inflammatory markers relevant to cardiovascular risk.

A 2025 RCT (PMID: 40280611) studying ashwagandha for long COVID recovery included cardiovascular and inflammatory markers, consistent with the broader anti-inflammatory evidence profile.

What the Research Has NOT Shown

Critical honesty is required here:

• No cardiovascular outcome trial exists: No study has enrolled patients with existing heart disease and followed them long enough to measure cardiovascular events (heart attacks, strokes, cardiovascular mortality). Biomarker improvements do not guarantee event reduction.
• Blood pressure data is inconsistent: Some studies show modest blood pressure reductions; others show no effect. No large dedicated trial has studied ashwagandha for hypertension specifically.
• Most lipid studies were small and short: The cholesterol improvements in the 2020 meta-analysis were drawn from studies that were predominantly under 100 participants and ran for 8–12 weeks. Long-term lipid effects are unknown.
• No comparison with statins or cardiovascular medications: There is no head-to-head data comparing ashwagandha to evidence-based cardiovascular treatments.

The Thyroid Interaction: Important for Heart Health Patients

A 2023 systematic review (PMID: 37013429) documented that ashwagandha improved thyroid hormone levels (TSH, T3, T4) in people with subclinical hypothyroidism. Thyroid function has direct cardiovascular implications — hypothyroidism is associated with dyslipidaemia and increased cardiovascular risk.

However, the same mechanism creates an important caution: people taking thyroid medication (levothyroxine) who use ashwagandha may experience changes in their effective thyroid dose. Thyroid function should be monitored if ashwagandha is added to an existing thyroid medication regimen.

What This Means in Practice

The stress-cardiovascular relay is real and well-documented. Ashwagandha addresses it upstream — through cortisol modulation, lipid profile improvement, and enhanced aerobic capacity — rather than directly targeting cardiovascular pathology.

For someone managing cardiovascular risk factors alongside chronic stress, the evidence for ashwagandha as an adjunctive tool is more substantive than it might appear at first glance. The convergence of lipid improvements, cortisol reduction, and VO2max enhancement across several independent studies suggests a consistent mechanistic direction.

Critical caveats for cardiovascular patients specifically:

• Consult your cardiologist or GP before adding ashwagandha if you are on statins, antihypertensives, or other cardiovascular medications. Potential additive effects on blood pressure and lipids require monitoring.
• This is not a replacement for evidence-based cardiovascular treatment. Statins, ACE inhibitors, and lifestyle modification have decades of outcome data. Ashwagandha does not.
• The aerobic capacity improvement is probably the most directly actionable finding — if ashwagandha helps you train harder and recover faster, the cardiovascular benefits of sustained exercise are well-established independently.

Teelixir's Formulation: Why Full-Spectrum Extraction Matters

The anti-inflammatory and lipid-modulating effects attributed to ashwagandha are primarily associated with its withanolide fraction — particularly withaferin A and withanolide D, which are fat-soluble compounds not accessible via aqueous extraction alone.

Our dual extraction process (hot water + ethanol) captures both the water-soluble beta-glucan and saponin fractions AND the fat-soluble withanolide fraction. Hot-water-only extracts will have a different and likely reduced withanolide profile.

Full specifications of our certified organic ashwagandha: root only, 10:1 extraction ratio, ≥2.5% withanolides by HPLC, ACO certified organic, Di Tao sourced from India, third-party tested for heavy metals and microbials on every batch.

Should You Take Ashwagandha for Heart Health?

The Bottom Line

Ashwagandha's cardiovascular relevance comes from the stress-cardiovascular relay: chronic stress damages cardiovascular health through multiple simultaneous pathways, and ashwagandha has documented effects on several of those pathways simultaneously.

The lipid improvements, cortisol reduction, and VO2max enhancement form a mechanistically coherent case for cardiovascular risk factor management — particularly for people whose cardiovascular risk profile is substantially driven by chronic stress and the cortisol cascade.

It is not a heart medication. For established cardiovascular disease, pharmaceutical evidence-based treatment is primary. But as one component of a comprehensive cardiovascular risk management strategy that includes exercise, diet, and stress management, our certified organic ashwagandha has a stronger evidence base than most people realise.

Third-Party Tested • ACO Certified • Di Tao Sourced

Teelixir Organic Ashwagandha Root (10:1)

Full-spectrum dual extract. Root only. ≥2.5% withanolides by HPLC. Heavy metal tested and certified every batch.

View Product

Continue Your Research

• Ashwagandha Benefits: The Complete Evidence-Based Guide
• Ashwagandha Dosage Guide: What Clinical Trials Actually Used
• Ashwagandha Side Effects: The Tolerance Threshold and What 29+ Clinical Trials Reveal
• Ashwagandha for Gut Health: The Stress-Gut Axis Short-Circuit
• Ashwagandha and Liver Health: Safety, Evidence, and the Hepatic Burden Equation
• Ashwagandha for Diabetes and Blood Sugar: The Stress-Glycaemia Loop
• Ashwagandha for Immune Support: The Immunostat Principle
• Ashwagandha and Cancer Research: The Petri Dish Problem

← Back to Ashwagandha Research Hub